Surgery Partners, Inc. (NASDAQ: SGRY) Shareholder Derivative Investigation

GRABAR LAW OFFICE INVESTIGATES POTENTIAL SHAREHOLDER DERIVATIVE ACTION ON BEHALF OF SHAREHOLDERS OF SURGERY PARTNERS, INC. (NASDAQ: SGRY)

The United States Attorney recently announced that Logan Laboratories, Inc. (Logan Labs), Tampa Pain Relief Centers, Inc. (Tampa Pain), and two of their former executives, Michael T. Doyle and Christopher Utz Toepke, have agreed to pay a total of $41 million to resolve alleged violations of the False Claims Act for billing Medicare, Medicaid, TRICARE, and other federal health care programs for medically unnecessary Urine Drug Testing (UDT). Both Labs are subsidiaries of Surgery Partners, Inc. 

Current Surgery Partners, Inc. shareholders who purchased shares of the Company’s stock in the past few years have standing to seek corporate governance reforms, and possibly the return of funds back to the company coffers and potentially a court approved incentive award if appropriate.

If you have held Surgery Partners shares continuously for the past several years and would like to learn more at no cost to you, fill out the form provided or contact us at jgrabar@grabarlaw.com.

ATTORNEY ADVERTISING DISCLAIMER: These materials have been prepared by the Grabar Law Office for informational purposes only and does not constitute legal advice. This information is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Online readers should not act upon this information without seeking professional counsel. Prior results referred to in these materials do not guarantee or suggest a similar result in other matters.

Please enter your name.
Please enter a valid phone number.
Please enter a message.

Grabar Law

Leave a Comment





Categories

Subscribe!